Q3 Earnings Estimate for Medtronic Issued By Leerink Partnrs

Medtronic PLC (NYSE:MDT) – Analysts at Leerink Partnrs decreased their Q3 2026 earnings estimates for shares of Medtronic in a research note issued to investors on Tuesday, November 18th. Leerink Partnrs analyst M. Kratky now forecasts that the medical technology company will post earnings of $1.33 per share for the quarter, down from their prior estimate of $1.36. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic’s Q2 2027 earnings at $1.44 EPS, Q4 2027 earnings at $1.79 EPS, FY2027 earnings at $6.10 EPS and FY2030 earnings at $7.70 EPS.

MDT has been the topic of several other research reports. Robert W. Baird upped their price objective on Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research report on Wednesday. Wells Fargo & Company boosted their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday. Royal Bank Of Canada upped their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Truist Financial boosted their price objective on shares of Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $109.33.

Medtronic Trading Down 0.3%

Shares of NYSE MDT traded down $0.30 during midday trading on Thursday, hitting $100.05. The company’s stock had a trading volume of 913,895 shares, compared to its average volume of 7,499,413. Medtronic has a 12-month low of $79.29 and a 12-month high of $102.59. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm has a market cap of $128.33 billion, a P/E ratio of 27.58, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The business’s 50 day moving average is $94.80 and its two-hundred day moving average is $90.70.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.

Hedge Funds Weigh In On Medtronic

A number of large investors have recently bought and sold shares of MDT. Brighton Jones LLC lifted its stake in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. OneAscent Financial Services LLC grew its stake in Medtronic by 4.9% in the first quarter. OneAscent Financial Services LLC now owns 3,772 shares of the medical technology company’s stock valued at $337,000 after purchasing an additional 175 shares during the last quarter. J.W. Cole Advisors Inc. raised its holdings in Medtronic by 90.4% in the first quarter. J.W. Cole Advisors Inc. now owns 18,617 shares of the medical technology company’s stock worth $1,673,000 after purchasing an additional 8,839 shares in the last quarter. Crestwood Advisors Group LLC lifted its position in shares of Medtronic by 6.3% during the first quarter. Crestwood Advisors Group LLC now owns 6,935 shares of the medical technology company’s stock valued at $623,000 after buying an additional 411 shares during the last quarter. Finally, PFG Advisors lifted its position in shares of Medtronic by 55.0% during the first quarter. PFG Advisors now owns 4,144 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,471 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.26% of the stock is owned by corporate insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.